|
| Primary information |
|---|
| ID | 10407 |
| Therapeutic ID | Th1066 |
| Protein Name | Ibritumomab |
| Sequence | >Th1066_Ibritumomab
QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR
|
| Molecular Weight | 143375.5 |
| Chemical Formula | C6382H9830N1672O1979S54 |
| Isoelectric Point | 7.91 |
| Hydrophobicity | -0.359 |
| Melting point | 71 |
| Half-life | 0.8 hours (mammalian reticulocytes, in vitro) |
| Description | Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. |
| Indication/Disease | For treatment of non-Hodgkin's lymphoma |
| Pharmacodynamics | Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90. |
| Mechanism of Action | The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production |
| Absorption | NA |
| NA |
| Clearance | Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days. |
| Categories | Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antigens, CD20, Blood Proteins, Cancer immunotherapy, CD20-directed Antibody Interactions, CD20-directed Radiotherapeutic Antibody, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Immunotherapy, Lymphoma, B-Cell, Myelosuppressive Agents, Proteins, Radiopharmaceutical Activity, Serum Globulins, Therapeutic Radiopharmaceuticals, Various Therapeutic Radiopharmaceuticals, Yttrium Radioisotopes |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | NA |
| Useful Link 2 | NA |
| Remarks | NA |